Work

P3.18.28 KEYMAKER-U01 Substudy 01G: Pembrolizumab+Patritumab Deruxtecan±Chemotherapy in Previously Untreated Stage IV NSCLC

Year: 2025

Type: article

Source: Journal of Thoracic Oncology

DOI: 10.1016/j.jtho.2025.09.1043

Authors: M.L. Johnson, T. Csoszi, Z. Szalai, J. Bar, N. Peled, B.C. Cho, Y.J. Kim, D. Kowalski, E. Nadal, J. Niu, J.F. Gainor, C. Aggarwal, D.P. Carbone, K.H. Dragnev, K. Chen, D. Sternberg, B. Zhao, H. Zhou, A. Namakydoust, V. Velcheti

Institutions: Sarah Cannon, Semmelweis University, Petz Aladár Megyei Oktató Kórház, Tel Aviv University, Sheba Medical Center, Shaare Zedek Medical Center, Severance Hospital, Yonsei Cancer Hospital, Seoul National University Bundang Hospital, The Maria Sklodowska-Curie National Research Institute of Oncology, Institut d'Investigació Biomédica de Bellvitge, Institut Català d'Oncologia, Banner MD Anderson Cancer Center, Massachusetts General Hospital, University of Pennsylvania, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Pelotonia, Dartmouth Health, Dartmouth Cancer Center, MedStar Franklin Square Medical Center, Daiichi Sankyo (United States), Merck & Co., Inc., Rahway, NJ, USA (United States), NYU Langone Health, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, New York University

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4415519088

FWCI:

Cites:

Cited by:

Related to: